Literature DB >> 26522808

Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy.

Seha Park1, Junshik Hong2, Incheol Hwang3, Jeong-Yeal Ahn4, Eun Yeong Cho5, Jinny Park5, Eun Kyung Cho5, Dong Bok Shin5, Jae Hoon Lee5.   

Abstract

OBJECTIVES: The purpose of this prospective observational study is to evaluate the relation of the comprehensive geriatric assessment (CGA) to tolerability and survival of multi-agent chemotherapy for curative intent in elderly patients with aggressive non-Hodgkin lymphoma (NHL).
MATERIALS AND METHODS: Patients who were 1) age ≥65 years, 2) newly diagnosed aggressive NHL, and 3) treated with multi-agent chemotherapy within 2 weeks from the time of diagnosis were enrolled from January 2011 to June 2014. Baseline clinical, laboratory, and CGA data being composed of Mini Nutritional Assessment-Short Form (MNA-SF), Korean version of Mini Mental Status Exam, Korean-Geriatric Depression Scale, and Groningen Frailty Index (GFI), were collected and analyzed for the relation to the outcome factors.
RESULTS: Seventy patients were included; the median age was 73.5 years, 27 (38.6%) patients were Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 or more, and half of the patients were high or high-intermediate risk by age-adjusted international prognostic index (aaIPI). Most patients received CHOP or CHOP-like chemotherapy. Factors affecting discontinuation of chemotherapy within 12 weeks were poor MNA-SF, poor GFI, poor PS, and presence of B symptom. Among those, poor MNA-SF was independent of other variables in multivariate analysis. Poor MNA-SF, bone marrow involvement, and baseline anemia of hemoglobin<10g /dL were found to be independent factors associated with inferior overall survival whereas aaIPI factors were not.
CONCLUSION: MNA-SF predicted tolerability to multi-agents chemotherapy and overall survival in elderly patients with aggressive NHL who were treated with multi-agent chemotherapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Elderly; Geriatric assessment; Non-Hodgkin lymphoma

Mesh:

Substances:

Year:  2015        PMID: 26522808     DOI: 10.1016/j.jgo.2015.10.183

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN: 1879-4068            Impact factor:   3.599


  6 in total

1.  Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation.

Authors:  Maria Queralt Salas; Eshetu G Atenafu; Ora Bascom; Leeann Wilson; Wilson Lam; Arjun Datt Law; Ivan Pasic; Dennis Dong Hwan Kim; Fotios V Michelis; Zeyad Al-Shaibani; Armin Gerbitz; Auro Viswabandya; Jeffrey Howard Lipton; Jonas Mattsson; Shabbir M H Alibhai; Rajat Kumar
Journal:  Bone Marrow Transplant       Date:  2020-06-30       Impact factor: 5.483

2.  Ready for prime time: role for geriatric assessment to improve quality of care in hematology practice.

Authors:  Heidi D Klepin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 3.  Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.

Authors:  Mengyang Di; Scott F Huntington; Adam J Olszewski
Journal:  Oncologist       Date:  2020-12-09       Impact factor: 5.837

4.  Nutritional status according to the mini nutritional assessment (MNA)® as potential prognostic factor for health and treatment outcomes in patients with cancer - a systematic review.

Authors:  G Torbahn; T Strauss; C C Sieber; E Kiesswetter; D Volkert
Journal:  BMC Cancer       Date:  2020-06-26       Impact factor: 4.430

Review 5.  Geriatric assessment in older patients with a hematologic malignancy: a systematic review.

Authors:  Ellen R M Scheepers; Ariel M Vondeling; Noortje Thielen; René van der Griend; Reinhard Stauder; Marije E Hamaker
Journal:  Haematologica       Date:  2020-05-07       Impact factor: 9.941

6.  Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy.

Authors:  Anita J Kumar; Jason Nelson; Angie Mae Rodday; Andrew M Evens; Jonathan W Friedberg; Tanya M Wildes; Susan K Parsons
Journal:  J Geriatr Oncol       Date:  2021-07-28       Impact factor: 3.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.